Tag: tumor marker test

Hospitals Recognize Need for Uniform Lab Test Data

By Joseph Burns, from the Volume XX No. 12 - September 9, 2013 issue

CEO SUMMARY: Hospitals may soon insist that payers allow their in-house labs to provide outpatient testing regardless of exclusive managed care contracts with national lab companies. The migration to accountable care organizations (ACOs) and medical homes makes it essential that physicians have access to lab data across the entire continuum of care. Standardization of reporting

View Article

Bio-Reference Enters DNA Sequencing Market

By Robert Michel, from the Volume XIII No. 12 - September 5, 2006 issue

CEOSUMMARY: Bio-Reference Laboratories has just placed an unexpected bet on the wide-open opportunities in genetic testing. The acquisition of GeneDX brings it a respected team of geneticists, capabilities in full DNA sequencing, and a proven track record in testing for rare and complex hereditary diseases. It also opens a new lab testing market niche for

View Article

Volume XXVI No. 2 – February 4, 2019

NOW THAT MOST HOSPITALS ARE INCLUDED as applicable laboratories that must report their PAMA private payer lab test price data to the Centers for Medicare and Medicaid Services, managers of those labs will benefit from the incisive analysis in this issue of the lessons learned during the 2017 PAMA reporting cycle. THE DARK REPORT further offers recommendations on how labs can do a better job of gathering and reporting their own data to CMS. Also, TDR delivers an exclusive analysis of why the Government Accounting Office's assertion that CMS will be paying billions more for Part B clinical lab tests is simply wrong.

See the full table of contents

Tag: tumor marker test

Enter Your Login Credentials